NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Want to cut your energy bills? Here’s how five experts are doing it 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
NEW YORK, March 03, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Endologix, Inc. (NASDAQ:ELGX) securities between August 2, 2016 and November 16, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/endologix-inc. There is no cost or obligation to you.
According to the complaint, defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix EndoVascular Aneurysm Sealing System; and (2) as a result, Endologix’s public statements were materially false and misleading at all relevant times.
On November 16, 2016, Endologix announced that the FDA requested two-year follow-up data on patients enrolled in the EVAS-FORWARD IDE study to assess Nellix. On this news, shares of Endologix fell $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016, damaging investors.
If you suffered a loss in Endologix you have until March 6, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/endologix-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
